Woodcock Hopes I-SPY 2 Trial Is 'Blazing The Trail' For Future Adaptive Design Uptake
CDER director renews US FDA's support for complex trials, but acknowledges that sponsors are still hesitant to adopt them.
CDER director renews US FDA's support for complex trials, but acknowledges that sponsors are still hesitant to adopt them.